Flucelvax Tetra

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

A/Darwin/6/2021(H3N2)-like strain (A/Darwin/11/2021, wild type) / A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022 CVR-167) / B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021) / B/Phuket/3073/2013-like virus (B/Singapore/INFTT-16-0610/2016, wild type)

Available from:

Seqirus Netherlands B.V.

ATC code:

J07BB02

INN (International Name):

influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

Therapeutic group:

вирус на грип, инактивированная, сплит или повърхностен антиген

Therapeutic area:

Грип, Човек

Therapeutic indications:

Prophylaxis of influenza in adults and children from 2 years of age. Flucelvax на Тетра трябва да се прилага в съответствие с официалните препоръки.

Product summary:

Revision: 14

Authorization status:

упълномощен

Authorization date:

2018-12-12

Patient Information leaflet

                                24
Б. ЛИСТОВКА
25
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
FLUCELVAX TETRA ИНЖЕКЦИОННА СУСПЕНЗИЯ В
ПРЕДВАРИТЕЛНО НАПЪЛНЕНА СПРИНЦОВКА
Ваксина срещу грип (повърхностен
антиген, инактивирана, получена в
клетъчни култури)
[Influenza vaccine (surface antigen, inactivated, prepared in cell
cultures)]
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПОЛУЧАВАТЕ ТОВА
ЛЕКАРСТВО, ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА
ЗА ВАС ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар,
фармацевт или
медицинска сестра. Това включва и
всички възможни нежелани реакции,
неописани в
тази листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Flucelvax Tetra и за какво
се използва
2.
Какво трябва да знаете, преди да Ви се
приложи Flucelvax Tetra
3.
Как се дава Flucelvax Tetra
4.
Възможни нежелани реакции
5.
Как да съхранявате Flucelvax Tetra
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА FLUCELVAX TETRA
И ЗА КАКВО СЕ ИЗПОЛЗВА
Flucelvax Tetra е ваксина срещу грип
(инфлуенца). Flucelvax Tetra е приготвена о
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Flucelvax Tetra инжекционна суспензия в
предварително напълнена спринцовка
Ваксина срещу грип (повърхностен
антиген, инактивирана, получена в
клетъчни култури)
[Influenza vaccine (surface antigen, inactivated, prepared in cell
cultures)]
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Инактивирани повърхностни антигени
от грипен вирус [хемаглутинин
(haemagglutinin) и
невраминидаза (neuraminidase)] от следните
щамове*:
A/Wisconsin/67/2022 (H1N1)pdm09-подобен щам
(A/Georgia/12/2022 CVR-167) 15 микрограма
HA**
A/Darwin/6/2021 (H3N2)-подобен щам (A/Darwin/11/2021, див
тип) 15 микрограма HA**
B/Austria/1359417/2021-подобен щам
(B/Singapore/WUH4618/2021, див тип) 15 микрограма
HA**
B/Phuket/3073/2013-подобен щам
(B/Singapore/INFTT-16-0610/2016, див тип) микрограма
HA**
на 0,5 ml доза
……………………………………….
*
произведени в клетъчна култура от
кучешки бъбрек Madin Darby (Madin Darby Canine
Kidney, MDCK)
**
хемаглутинин
Ваксината отговаря на препоръките на
Световната здравна организация (СЗО)
(за северното
полукълбо) и решението на ЕС за СЕЗОН
2023/2024.
Flucelvax Tetra може да съдържа следи от
бета-пропиолактон,
цетилтриметиламониев бромид и
полисорбат 80 (вж. точка 4.3).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФО
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 15-12-2023
Public Assessment Report Public Assessment Report Spanish 18-11-2020
Patient Information leaflet Patient Information leaflet Czech 15-12-2023
Public Assessment Report Public Assessment Report Czech 18-11-2020
Patient Information leaflet Patient Information leaflet Danish 15-12-2023
Public Assessment Report Public Assessment Report Danish 18-11-2020
Patient Information leaflet Patient Information leaflet German 15-12-2023
Public Assessment Report Public Assessment Report German 18-11-2020
Patient Information leaflet Patient Information leaflet Estonian 15-12-2023
Public Assessment Report Public Assessment Report Estonian 18-11-2020
Patient Information leaflet Patient Information leaflet Greek 15-12-2023
Public Assessment Report Public Assessment Report Greek 18-11-2020
Patient Information leaflet Patient Information leaflet English 15-12-2023
Public Assessment Report Public Assessment Report English 18-11-2020
Patient Information leaflet Patient Information leaflet French 15-12-2023
Public Assessment Report Public Assessment Report French 18-11-2020
Patient Information leaflet Patient Information leaflet Italian 15-12-2023
Public Assessment Report Public Assessment Report Italian 18-11-2020
Patient Information leaflet Patient Information leaflet Latvian 15-12-2023
Public Assessment Report Public Assessment Report Latvian 18-11-2020
Patient Information leaflet Patient Information leaflet Lithuanian 15-12-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-12-2023
Public Assessment Report Public Assessment Report Lithuanian 18-11-2020
Patient Information leaflet Patient Information leaflet Hungarian 15-12-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 15-12-2023
Public Assessment Report Public Assessment Report Hungarian 18-11-2020
Patient Information leaflet Patient Information leaflet Maltese 15-12-2023
Public Assessment Report Public Assessment Report Maltese 18-11-2020
Patient Information leaflet Patient Information leaflet Dutch 15-12-2023
Public Assessment Report Public Assessment Report Dutch 18-11-2020
Patient Information leaflet Patient Information leaflet Polish 15-12-2023
Public Assessment Report Public Assessment Report Polish 18-11-2020
Patient Information leaflet Patient Information leaflet Portuguese 15-12-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 15-12-2023
Public Assessment Report Public Assessment Report Portuguese 18-11-2020
Patient Information leaflet Patient Information leaflet Romanian 15-12-2023
Public Assessment Report Public Assessment Report Romanian 18-11-2020
Patient Information leaflet Patient Information leaflet Slovak 15-12-2023
Public Assessment Report Public Assessment Report Slovak 18-11-2020
Patient Information leaflet Patient Information leaflet Slovenian 15-12-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 15-12-2023
Public Assessment Report Public Assessment Report Slovenian 18-11-2020
Patient Information leaflet Patient Information leaflet Finnish 15-12-2023
Public Assessment Report Public Assessment Report Finnish 18-11-2020
Patient Information leaflet Patient Information leaflet Swedish 15-12-2023
Public Assessment Report Public Assessment Report Swedish 18-11-2020
Patient Information leaflet Patient Information leaflet Norwegian 15-12-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 15-12-2023
Patient Information leaflet Patient Information leaflet Icelandic 15-12-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 15-12-2023
Patient Information leaflet Patient Information leaflet Croatian 15-12-2023
Public Assessment Report Public Assessment Report Croatian 18-11-2020